Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 8/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22200653 | 0.91 | MTOR (0.38) | MTORPIK3CARORC | |
| SCHEMBL22200818 | 0.88 | MTOR (0.36) | MTORPIK3CARORC | |
| SCHEMBL22200802 | 0.86 | MTOR (0.41) | MTOREGFRFGFR1SRCFGFR2 | |
| SCHEMBL22200785 | 0.85 | FGFR1 (0.45) | MTOREGFRFGFR1SRCFGFR2 | |
| SCHEMBL25035336 | 0.82 | PKM (0.41) | MTOREGFRFGFR1SRCFGFR2 | |
| SCHEMBL22200350 | 0.78 | USP2 (0.38) | MTOREGFRFGFR1SRCFGFR2 | |
| SCHEMBL22200792 | 0.78 | MTOR (0.35) | MTORPIK3CARORC | |
| SCHEMBL22200825 | 0.77 | CYP1A2 (0.36) | MTORRORC | |
| SCHEMBL22200378 | 0.77 | ERN1 (0.34) | EGFRFGFR1SRC | |
| SCHEMBL22200739 | 0.77 | BTK (0.43) | MTOREGFRFGFR1SRCFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020142612-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH, INC. (US) | 2020-07-09 | — | — | WO | disclosed |